NVS' Fabhalta improves the average hemoglobin level compared to baseline in adult patients with PNH who switched from anti-C5 ...

Novartis has reported positive topline outcomes from the multicentre Phase IIIB APPULSE-PNH trial of oral Fabhalta (iptacopan ...

Novartis reports positive Phase 3B results for Fabhalta in PNH patients, highlighting improved hemoglobin levels and ...

Novartis today announced positive top-line results from APPULSE-PNH, a Phase IIIb study on the efficacy and safety of ...

Fabhalta (iptacopan) is a prescription drug that’s used to treat a rare type of kidney disease and a rare blood disorder. Fabhalta comes as an oral capsule that’s typically taken twice per day.

Novartis (NVS) announced positive topline results from APPULSE-PNH, a Phase IIIB study evaluating the efficacy and safety of twice-daily oral ...

Novartis’ Fabhalta improved hemoglobin levels in patients with a rare blood disorder who switched from anti-C5 therapies, ...

New phase IIIB data shows Novartis Fabhalta improved haemoglobin levels in adult patients with PNH who switched from anti-C5 therapy: Basel Saturday, December 7, 2024, 10:00 Hrs [ ...

Promising topline results from a phase 3B study show the efficacy and quality of life (QOL) improvements of iptacopan ...

Novartis (NYSE:NVS) reported positive Phase 3b data from a study of its drug Fabhalta for the treatment of the rare blood ...